To further explore the relationship between high CASP4 expression and the clinical presentation of glioma patients, we investigated the relationship between CASP4 expression and the characteristics of age, gender, molecular subtype, pathological grade, clinical stage, isocitrate dehydrogenase (IDH) mutation, 1p/19q codeletion, and MGMT methylation status. This evidence concerns the gene CASP4 and central nervous system cancer.